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AbstrACt
background Gastro-oesophageal reflux is prevalent 
in preterm infants. Despite widespread use in clinical 
practice, there is still much controversy over the efficacy 
and safety of drug interventions, particularly antacid 
therapy.
Objective To systematically review the effects of antacid 
therapy on preterm infants with symptoms of gastro-
oesophageal reflux, and to assess the safety of these 
interventions.
Methods We carried out an electronic search of the 
Cochrane central register of controlled trials (CENTRAL, 
The Cochrane Library), MEDLINE (1966–present), EMBASE 
(1980–present) and CINAHL (1982–present) as well as 
other online sources. Participants were preterm infants 
(<37 weeks gestation) with gastro-oesophageal reflux 
disease who were receiving care on a neonatal unit. We 
assessed the effects of histamine-2 receptor antagonists, 
proton pump inhibitors and alginates against placebo, 
primarily to see if they reduced the symptoms of reflux.
results Six studies were included in this review. Meta-
analysis could not be carried out due to a lack of studies 
assessing the same intervention with the same outcomes. 
Omeprazole therapy significantly reduced the oesophageal 
acid exposure percentage time with pH<4 (p<0.01) 
and sodium alginate significantly decreased gastro-
oesophageal reflux episodes (p=0.024). Metoclopramide 
and ranitidine showed a significant increase in gastro-
oesophageal reflux disease symptoms versus placebo 
(p<0.04). No significant results were found for the use of 
esomeprazole or lansoprazole versus placebo.
Conclusions There is insufficient evidence available to 
conclude whether antacid therapy is effective or safe when 
treating gastro-oesophageal reflux disease in preterm 
infants. Further research is needed into this topic and 
caution should be taken when administering antacids to 
preterm infants.
trial registration number CRD42017078778
bACkgrOund
Gastro-oesophageal reflux (GOR) is a prom-
inent condition among preterm infants. 
Symptoms such as apnoeas, desaturation, 
bradycardia, vomiting, poor weight gain and 
irritability have been attributable to GOR, 
which is called gastro-oesophageal reflux 
disease (GORD), when symptoms are severe. 
GORD has been reported to cause irritability, 
frequent vomiting, apnoea and bradycardia, 
aspiration pneumonia, aversion to feeding 
and exacerbation of chronic lung disease 
in term and preterm infants with associated 
resource implications from longer hospital 
stays.
Despite this, controversy remains over how 
it should be treated. Currently, non-pharma-
cological therapies are generally the first line 
of treatment in GORD with pharmacolog-
ical therapies reserved for those who do not 
respond.1 Antacids containing alginate, hista-
mine-2 receptor antagonists (H2 RAs) and 
proton pump inhibitors (PPI) are among the 
most common interventions used with 60%, 
53% and 23% of UK neonatal units using 
these products, respectively.2
Studies have also shown a significant 
correlation between the use of H2 RAs 
and important complications.3 4 Guillet et 
al showed H2-blocker use was associated 
with an increased incidence of necrotising 
What is already known on this topic?
 ► Gastro-oesophageal reflux is a prominent condition 
among preterm infants.
 ► Antacids are often used to treat gastro-oesophageal  
reflux disease (GORD), despite the lack of good qual-
ity evidence to support its use.
 ► Studies have shown a significant positive correlation 
between the use of histamine-2 receptor antago-
nists and important complications.
What this study hopes to add?
 ► There is limited evidence supporting the use of ant-
acids in preterm infants.
 ► Omeprazole reduced gastric and oesophageal pH, 
but did not alter GORD symptoms. Esomeprazole and 
lansoprazole had no significant effect on GORD signs 
and symptoms.
 ► Combined use of ranitidine and metoclopramide ap-
pears countereffective, with placebo periods giving 
less bradycardia episodes versus drug periods.
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enterocolitis (NEC) (OR 1.71; 95% CI 1.34 to 2.19; 
p<0.0001).3
There continues to be a widespread use of antacid 
therapy in neonatal units today despite the evidence gaps. 
This review was carried out to systematically evaluate the 
evidence of efficacy and safety of antacid treatment for 
GORD in preterm infants and to highlight potential 
areas for future research.
ObjeCtives
Primary objective
To assess the efficacy of antacid therapy in preterm 
infants diagnosed with GORD.
secondary objective
To assess the safety of antacid therapy in preterm infants 
diagnosed with GORD.
MAteriAls And MethOds
We used Preferred Reporting Items for Systematic Reviews 
and Meta-analyses guidelines and the Cochrane Hand-
book of Systematic Reviews of Interventions approach 
for conducting and reporting systematic reviews and 
meta-analyses of randomised controlled trials (RCTs).5 6 
The methodology of this systematic review was published 
in PROSPERO (www. crd. york. ac. uk/ PROSPERO; ref 
CRD42017078778).
search methods for identification of studies
MEDLINE/PubMed, Embase, Wiley Online Library, 
Cochrane Library and Web of Science databases were 
searched to identify trials of antacid therapy in preterm 
infants. Databases were screened for publications from 
the earliest available date until 15 October 2017. No 
language restrictions were applied. Ethical approval 
was not required because only published articles were 
included in this review. A database search of  clinicaltrials. 
gov for ongoing and completed trials was also carried 
out, using the search terms infant or preterm and reflux 
or gastroesophageal reflux. Trials reported as abstracts 
or letters to the editor were included if sufficient data 
to fulfil the inclusion criteria were presented within the 
report, or provided by authors. Full search strategy is 
presented in online supplementary appendix 1.
eligibility criteria
All relevant randomised trials involving preterm infants 
(<37 weeks gestation) with GORD (clinical diagnosis 
and/or 24 hours intraoesophageal pH monitoring, or 
impedance studies) receiving care on a neonatal unit. 
Crossover, randomised trials or quasi-randomised studies, 
described in some way as to suggest or imply that the 
study was randomised if the demographic detail of each 
group was similar were included.
types of interventions
We included all available RCTs evaluating antacid ther-
apies for GOR in preterm neonates. Antacid therapy 
(administered by any method) should have been 
commenced after the diagnosis of GORD and continued 
for any duration.
The interventions considered were:
 ► H2 RAs versus a placebo or standard care/non-phar-
macological therapy.
 ► PPIs versus a placebo or standard care/non-pharma-
cological therapy.
 ► Alginates versus a placebo or standard care/non-phar-
macological therapy.
Trials were not limited by dose, frequency or duration 
of intervention.
selection of studies
Paired reviewers (ED, CM, BS, JD) independently 
screened titles, abstracts and then full texts for eligibility, 
assessed risk of bias and collected data from included 
studies. Any disagreement between reviewers was resolved 
through discussion or adjudication by a third reviewer 
(BS, JD). In case of duplicate publications, the most 
recent and updated report of the study was included.
risk of bias and quality of evidence assessment
The Cochrane Risk-of-Bias Tool was used to assess the 
risk of bias.7 The quality of the evidence of outcomes was 
rated by the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) approach.8
data extraction
From each eligible study the following information was 
collected: study characteristics (eg, author name, year of 
publication, sample size, patient characteristics, antacid 
type, duration of intervention, dosage and any of our 
preplanned clinical outcomes).
Primary outcomes
A reduction in reflux symptoms assessed by a reflux 
index score or bedside symptom charts.9 Clinical symp-
toms include the following: total GOR episodes, vomit/
regurgitations, choking/coughing, bradycardia attrib-
uted to GOR, behavioural/crying, feeding difficulties, 
irritability or pain, recurrent postprandial apnoeas and 
oxygen desaturation within 2 hours postprandial period.
Secondary outcomes
 ► Time taken to establish full enteral feeds
 ► Length of hospital stay
 ► NEC (Bell’s stage 2 or greater)
 ► Suspected or proven sepsis
 ► Other adverse effects
statistical analysis
We planned to analyse treatment effects in the indi-
vidual trials using Review Manager 5.3 software, with 
risk ratio and risk difference for dichotomous data and 
mean difference for continuous data, with respective 
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95% CIs. However, given the small number of included 
studies, their varying methodologies and interventions, 
we judged quantitative meta-analysis to be inappropriate 
and instead report a narrative description of each study. 
Data are presented as reported in individual studies. We 
had also planned to conduct a number of subgroup anal-
yses, which are detailed in the study protocol. The small 
number of studies, with small sample sizes and variable 
methods precluded subgroup analyses.
results
description of studies
A total of 20 139 records were identified by the initial 
search; 18 909 were excluded as they were duplicates, or 
systematic reviews; 1230 titles and abstracts were screened 
and 1202 were excluded. Twenty-eight full-text articles were 
assessed for eligibility and six studies met our inclusion 
criteria (figure 1).
All included studies were double-blind, randomised, 
placebo-controlled trials. Four of the six were crossover 
trials (Wheatley and Kennedy,10 Omari et al,11 Corvaglia 
et al,12 Corvaglia et al13), while the remaining two were 
parallel trials (Orenstein et al14 and Davidson et al15).
The main characteristics of included RCTs are described 
in table 1 and excluded studies are summarised in online 
supplementary appendix 2.
Risks of bias assessments of trials are summarised in 
figure 2 and online supplementary appendix 3. The eval-
uations of the level of evidence of outcomes according to 
the GRADE approach are summarised in online supple-
mentary appendix 4.
Figure 1 Study flow diagram. RCT, randomised controlled trial.
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A total of 302 participants were enrolled in the six 
included trials, of which, four studies included only 
preterm infants. Omari et al11 included preterm infants 
between 34 and 40 weeks gestational age, Corvaglia et al12 
and Corvaglia et al13 included ≤33 weeks gestational age 
and Wheatley and Kennedy10 included those with a gesta-
tional age of <37 weeks at birth and a corrected gesta-
tional age at enrolment of <44 weeks. Orenstein et al14 
and Davidson et al15 included both preterm infants and 
full-term infants. The inclusion criteria for each study 
defined GORD differently (table 1).
Primary outcome: all six studies assessed various reflux 
symptoms. Four trials reported GOR episodes based 
on 24-hour pH/impedance monitoring.11–13 15 Three 
trials reported bradycardia (Davidson et al,15 Omari et 
al,11 Wheatley and Kennedy10) and three trials reported 
apnoea (Corvaglia et al,13 Davidson et al,15 Omari et al11). 
The other reported outcomes included vomiting, apnoea, 
bradycardia, oxygen desaturation, gagging, back arching 
and irritability/crying/fussing.10 11 14 15 None of the 
studies reported on the prespecified secondary outcomes, 
namely: time taken to establish full enteral feeds, length 
of hospital stay, NEC and suspected or proven sepsis. 
Orenstein et al looked at treatment-emergent adverse 
events (AEs) and serious adverse events (SAEs) including 
upper respiratory tract infections, constipation, derma-
titis, ear infections, fever, lower respiratory tract infection, 
respiratory tract congestion, rhinorrhoea, candidiasis, 
diarrhoea (excluding infective), vomiting, alkaline phos-
phatase increase and others.
effects of interventions
Sodium alginate (Gaviscon) versus placebo
Thirty-two patients with a median gestational age of 
30 weeks were enrolled in Corvaglia et al.12 Participants 
were fed eight times over a 24 hours period, with meals 
alternatively given with drug (‘drug-given’ (DG)) and 
without drug (‘drug-free’ (DF)). Twenty-eight patients 
with a median gestational age of 30 weeks were enrolled 
in Corvaglia et al.13 Participants were studied between the 
hours of 09:00 and 18:00, when they were recorded twice, 
for 3 hours each time, after one DG meal and one DF 
meal, the order of which was randomly chosen.
There was significant decrease in total GOR episodes 
detected only by pH monitoring, acid GOR episodes 
detected by multichannel intraluminal impedance moni-
toring, reflux index detected only by pH monitoring and 
proximal GORs.12 13
All other outcomes were not significant (liquid GORs, 
mixed GORs, non-acid GOR episodes detected by multi-
channel intraluminal impedance monitoring, non-acid 
MII-GOR-bolus exposure index and distal GORs).12 No 
differences in the number of total apnoea episodes, 
central apnoeas, obstructive apnoeas, mixed apnoeas, 
desaturations, bradycardia, pathological apnoeas were 
found between DG and DF periods (p value was not 
significant)13 (table 2).
esomeprazole versus placebo
Fifty-two patients with a mean gestational age of 31 were 
enrolled in the study by Davidson et al. One did not have 
valid efficacy data and was excluded from the reported 
results. Participants were randomly selected to receive 
either esomeprazole (n=25) or placebo (n=26), once 
daily, for up to 14 days.15
No significant results were obtained from this study, 
which was discontinued prematurely due to poor 
enrolment15 (table 3).
Omeprazole versus placebo
Ten preterm infants with a mean postmenstrual age of 
36.1±0.7 weeks and mean postnatal age of 50±9 days 
were enrolled in the study by Omari et al.11 Participants 
were given omeprazole for 7 days and placebo for 7 days 
in randomised order. At the end of each week of inter-
ventions, a 24-hour oesophageal and gastric pH moni-
toring study was performed. Analyses on the basis of pH 
recordings showed that omeprazole therapy significantly 
reduced the oesophageal acid exposure % time pH<4 and 
reduced gastric acidity % time pH<411 (table 3). There 
Figure 2 Risk of bias summary.
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were no significant changes to symptom frequency 
(vomiting, apnoea, bradycardia, choking, behavioural 
changes) or blood results.
lansoprazole versus placebo
One hundred sixty-two patients were enrolled in the 
study by Orenstein et al, 44 of whom were premature 
infants, with a median gestational age at birth of 35 (IQR 
25–39) weeks.13 Participants were randomly selected to 
take either lansoprazole (n=81) or a placebo (n=81) for 
up to 4 weeks. There was a 35% loss of follow-up for partic-
ipants receiving lansoprazole and 36% for participants 
receiving placebo. Lansoprazole and placebo produced 
identical responder numbers (54%). Responder status 
was defined as a ≥50% reduction from baseline in either 
percentage of feedings with crying episode(s) or duration 
(in minutes) of episodes averaged across feedings. No 
significant results were obtained from this trial. SAEs, 
particularly lower respiratory tract infections, occurred 
more frequently with lansoprazole than with placebo 
group (10 vs 2; p=0.032) (table 3).
Metoclopramide and ranitidine versus placebo
Eighteen patients were enrolled, and 17 completed the 
study, with a gestational age of 29±3 weeks. There was 
a significant decrease in the number of bradycardia 
episodes per day in the mean combined placebo time 
periods compared with the mean combined drug time 
periods (3.6 (SD 2.7) vs 4.6 (SD 3.1)), p=0.04), and in 
bradycardia episodes over time (p<0.001), with fewer 
episodes during placebo periods.10
Table 2 Effect of alginates (Gaviscon) use in preterm infants
Studies Antacids Control P values*
Corvaglia et al12
  Total GORs 49.00 (28.50–67.00) 58.50 (33.50–75.75) 0.024
  Liquid GORs 21.50 (12.25–32.00) 21.50 (13.50–39.75) 0.432
  Gaseous GORs 2.00 (0.25–7.50) 3.00 (0.00–14.75) 0.040
  Mixed GORs 3.00 (2.00–5.75) 3.00 (1.00–5.00) 0.614
  pH-GORs 17.00 (6.00–29.75 29.00 (13.50–44.50) 0.002
  aMII-GORs 4.00 (2.00–8.25) 6.00 (2.25–11.75) 0.050
  NaMII-GORs 19.00 (10.00–32.75) 18.50 (8.50–33.75) 0.743
  RIpH 4.0 (1.8–13.1) 7.6 (3.3–17.0) 0.030
  aMII-GOR-BEI 0.2 (0.1–0.6) 0.4 (0.1–1.0) 0.036
  NaMII-GOR-BEI 1.2 (0.5–1.9) 0.9 (0.5–1.7) 0.822
  Distal GORs (no.) 18.00 (11.25–27.00 15.00 (9.25–26.00) 0.959
  Proximal GORs (no.) 5.50 (4.00–9.00) 7.50 (3.00–12.00) 0.030
Corvaglia et al13
  Total GOR episodes 9 (0–33) 20.5 (1–42) 0.001
  pH-GOR 2 (0–26) 7.5 (0–23) 0.004
  aMII-GOR 1 (0–5) 3 (0–16) 0.001
  NaMII-GOR 4.5 (0–22) 6 (1–21) 0.145
  RIpH 0.9 (0–23.2) 8.4 (0–44.2) 0.001
  aMII-BEI 0.17 (0–2) 0.5 (0–8.1) 0.002
  NaMII-BEI 0.75 (0–5.7) 1.0 (0.1–9.2) 0.982
  Total apnoea episodes 9.5 (0–35) 9.5 (0–44) 0.99
  Central apnoeas 3.5 (0–25) 5 (0–34) 0.22
  Obstructive apnoeas 1 (0–8) 1 (0–10) 0.10
  Mixed apnoeas 3 (0–16) 4 (0–17) 0.98
  Desaturations 0.5 (0–10) 0 (0–12) 0.41
  Bradycardia 0 (0–3) 0 (0–3) 0.32
  Pathological apnoeas 0 (0–5) 0 (0–7) 0.69
Values are reported as median (IQR).
*P values as provided in the original publication. The level of significance was set at p≤0.05.
aMII-GOR, acid GOR episode detected by MII; aMII-GOR-BEI, acid MII-GOR-bolus exposure index; GOR, gastro-oesophageal reflux; MII, 
multichannel intraluminal impedance monitoring; NaMII-GOR, non-acid GOR episode detected by MII; NaMII-GOR-BEI, non-acid MII-GOR-
bolus exposure index; pH-GOR, GOR episodes detected only by pH monitoring; RIpH, reflux index detected only by pH monitoring.  o
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disCussiOn
This systematic review reveals that there is insufficient 
evidence to support the efficacy and safety of antacid 
therapies in preterm infants. Four out of the six studies 
included in the review were crossover trials, where the 
patient receives both interventions at different time inter-
vals. The carry-over effect, where the intervention taken 
in the first period is still effective when the second inter-
vention is being taken, is a major limitation in crossover 
designs. These effects cannot be estimated separately. To 
minimise the risk of a carry-over effect, it can be effec-
tive to allow a ‘washout’ period between interventions. 
Wheatley and Kennedy allowed a 24-hour washout period 
at the beginning of the second and third time periods.10 
Omari et al,11 Corvaglia et al12 and Corvaglia et al13 did 
not appear to have a washout period. When deciding 
whether to use a crossover design, it is important to 
consider whether the outcome that is being treated will 
change naturally over time. This does not seem like it 
would be an issue in the studies by Corvaglia et al12 and 
Corvaglia et al,13 due to the overall treatment and obser-
vation period being short at just 24 hours. It may be prob-
lematic, however, for the study by Omari et al,11 with each 
infant receiving a week of each intervention. Wheatley 
and Kennedy studied infants over a 2-week period and 
splits one intervention so it is given at the start and end of 
the 2-week period. This study shows a significant decrease 
in bradycardias over time, which may be evidential of a 
natural improvement of the outcome overtime, due to 
the infants’ growth.10
Alginates
Sodium alginate significantly reduced acid GOR episodes, 
although had no effect on the reduction of apnoeas. 
Corvaglia et al12 reports that participants were observed 
over a 24-hour period, and data were collected after eight 
meals. There may have been selective reporting in the 
study by Corvaglia et al,13 with authors only reporting data 
from a 6-hour period of observation instead of the full 
24 hours data, thus presenting more significant results. 
This discrepancy diminishes the validity of the reports 
and applicability to clinical practice.
Proton pump inhibitors
Omari et al showed that 0.7 mg/kg omeprazole given 
once daily was effective in reducing the frequency of 
acid reflux episodes and the overall degree of oesoph-
ageal acid exposure in premature infants.11 Despite the 
normalisation of acid reflux in most patients, the number 
of symptomatic events was not significantly changed. The 
drug-dosing regimen used appeared safe based on AE 
reporting and blood screening. However, due to the small 
number of participants enrolled in the study (n=10), it 
would be difficult to state whether this evidence is appli-
cable in everyday practice and more trials must be carried 
out into the efficacy of omeprazole. There were no signif-
icant differences in the number of GORD-related signs 
Table 3 Effect of proton pump inhibitors use in preterm infants
Studies Antacids Control
P values*Esomeprazole vs placebo 25 infants 26 infants 
Davidson et al15
  Total number of GORD-related signs and symptoms, percentage of 
change from baseline after 14 days of treatment
−14.7% 14.1% 0.92
  Gastrointestinal events, percentage of change from baseline −8.39% 10.16% 0.42
  Neurobehavioural events, percentage of change from baseline −3.54% −3.98% 0.94
  Cardiorespiratory events, percentage of change from baseline −38.94% −41.17% 0.89
Omeprazole vs placebo   10 infants 10 infants
Omari et al11
  Gastric acidity (%time pH<4), mean±SEM 13.9±5.1 53.8±6.8 <0.0005
  Oesophageal acid exposure (%time pH<4), mean±SEM 4.9±3.4 19.0±4.5 <0.01
  No. of acid GOR episodes, mean±SEM 119.4±20 59.6±26.7 <0.05
  No. of oesophageal acid GOR>5 min, mean±SEM 8.0±2.1 3.0±2.0 <0.01
Lansoprazole vs placebo 81 infants 81 infants
Orenstein et al14
  Primary efficacy: responder rate, n (%) 44 (54%) 44 (54%) NS
  AEs, n (%) 50 (62%) 37 (46%) NS
  SAEs, n (%) 10 (12%) 2 (2%) 0. 032
*P values as provided in the original publication.
AEs, adverse events; GOR, gastro-oesophageal reflux; GORD, gastro-oesophageal reflux disease; NS, not significant; SAEs, serious adverse 
events.
 o
n
 20 July 2018 by guest. Protected by copyright.
http://bmjpaedsopen.bmj.com/
bmjpo: first published as 10.1136/bmjpo-2018-000287 on 9 July 2018. Downloaded from 
8 Dermyshi E, et al. BMJ Paediatrics Open 2018;2:e000287. doi:10.1136/bmjpo-2018-000287
Open access
and symptoms between neonates receiving esomeprazole 
or lansoprazole versus placebo.14 15 SAEs occurred more 
frequently with lansoprazole than with placebo group. It 
is unclear whether loss to follow-up caused a significant 
imbalance in characteristics between lansoprazole and 
placebo group. Therefore, applicability into everyday 
practice is low because loss to follow-up can severely 
compromise validity as those lost to follow-up could 
have a different prognosis than those who complete the 
study. The number of AEs was similar between neonates 
receiving esomeprazole versus placebo. Both Orenstein et 
al and Davidson et al had notable conflicts of interest that 
were reported in the study, as shown in the online supple-
mentary appendix 3. The trials of both studies were spon-
sored by drug companies, which may have affected the 
design and outcomes of the trial as well as the reporting 
of results. However, no significant results were found in 
either trial, and so no results were reported in favour of 
the drug under trial.14 15
histamine-2 -receptor antagonists
A retrospective cohort study conducted by Romaine et 
al16 in the USA concluded that H2 blocker use was asso-
ciated with increased risk of the combined outcome of 
death, NEC or sepsis in hospitalised very low birthweight 
infants (VLBW). Another recent retrospective cohort 
study showed that ranitidine use was associated with an 
increased risk of infections and mortality in preterm 
infants, but not with NEC.17 Wheatley and Kennedy 
showed that ranitidine did not reduce, and may have 
increased, bradycardia episodes in preterm infants with 
bradycardia attributed to GOR.10 Wheatley and Kennedy 
compared the combination of two interventions together 
against a placebo, ranitidine, a H2 RA and metoclopr-
amide, a dopamine receptor antagonist. With regard to 
applicability, the data derived from this study actually 
suggest that combining ranitidine and metoclopramide 
may be detrimental to patients and should therefore be 
avoided in clinical practice, as it showed a significant 
increase in bradycardia episodes during drug periods. 
This may be caused by significant interactions between 
the two drugs that could either decrease the efficacy of 
either or both of drugs or perhaps cause AEs. Leucuta et 
al found pharmacokinetic changes, such as an increased 
half-life, in metoclopramide, when taken with raniti-
dine.18 It is also quite likely that this is a chance finding, 
given the small number of participants enrolled in the 
study (n=18). Previous studies into the combined efficacy 
of ranitidine and metoclopramide suggest that this treat-
ment is effective at increasing gastric pH and reducing 
the side effects of GORD, and do not mention any signif-
icant drug induced side effects or drug interactions.19 20
liMitAtiOns
A number of limitations are worth noting, not all studies 
met the inclusion criteria outlined in the methods. 
We initially stated that only preterm infants<37 weeks 
gestation were to be included in this review; however, 
both Davidson et al and Orenstein et al included data 
for full-term infants as well as preterm, some of whom 
were >37 weeks gestation. The authors were contacted 
to obtain exclusively preterm data, however, replies were 
not received. We included these studies in this review due 
to the high percentage of preterm infants enrolled in the 
trials. The methods stated that the only interventions that 
were to be considered were H2 RAs, PPIs and alginates; 
however, Wheatley and Kennedy assessed the combined 
effects of both metoclopramide (dopamine receptor 
antagonist) and ranitidine (H2 RA).10 We still decided 
to report this outcome as the inclusion of the H2 RA as 
it is of interest to the reader in general who must bear in 
mind this was a combined intervention. Studies included 
in the review were heterogeneous in terms of design, 
study characteristics such as age of participants and inter-
ventions considered for the treatment of GORD. Studies 
also had small sample sizes. This limits the conclusions 
that can be drawn from this review; however, it highlights 
the gaps in the evidence.
Agreements or disagreements with other studies or reviews
To our knowledge, this review is the first to look into the 
effects of antacids in preterm infants.
Terrin et al in a retrospective study of 274 VLBW infants 
reported that the risk of NEC, nosocomial infection and 
mortality were significantly higher in the infants exposed 
to ranitidine.4 However, non-prospective, non-controlled 
and unblinded design features limited its significance. 
A Cochrane review by Tighe et al looking at the effects 
of pharmacological treatment for the management of 
GORD in children concluded that although there is 
evidence to support pharmacological use in older chil-
dren, use in infants is unsupported due to lack of robust 
RCT evidence.21
Cohen et al in a recent review suggested that the use of 
GORD medications should only be used after non-phar-
macological measures have been taken with incomplete 
success as acid suppression may place immune-deficient 
infants and children at risk for the development of lower 
respiratory tract infections and nosocomial sepsis.22
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